Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial
Reid W. Merryman(Harvard University), Joshua Brody(New York University), Jennifer R. Brown(Dana-Farber Cancer Institute), Austin Kim(Dana-Farber Cancer Institute), Oreofe O. Odejide(Dana-Farber Cancer Institute), Cynthia K. Hahn(Boston University), Caron A. Jacobson(Dana-Farber Cancer Institute), Mark A. Murakami(Harvard University), Gottfried von Keudell(Beth Israel Deaconess Medical Center), Erin M. Parry(Broad Institute), Amy Bessnow(Harvard University), Philippe Armand(Harvard University), Inhye E. Ahn(Dana-Farber Cancer Institute), Heather Walker(Boston University), Matthew S. Davids(Dana-Farber Cancer Institute), Mingzeng Zhang(Boston University), Christine E. Ryan(Dana-Farber Cancer Institute), Eric D. Jacobsen(Dana-Farber Cancer Institute), David Qualls(Memorial Sloan Kettering Cancer Center), Ann S. LaCasce(Otsuka (Japan)), Aswin Sekar(Dana-Farber Cancer Institute), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Samantha Normilus(Dana-Farber Cancer Institute), Ioulia Vogiatzi(Boston University), Emily Sumpena(Boston University), Siri Sagedahl(Boston University), Hua‐Jay J. Cherng, Jenna Mahns(Boston University), Robert Redd(Harvard University)
Cited by 0
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k